等待开盘 09-17 09:30:00 美东时间
+0.040
+0.09%
今日重点评级关注:古根海姆:维持ProMIS Neurosciences"买入"评级,目标价从35美元升至69美元;BTIG:维持Cullinan Therapeutics"买入"评级,目标价从38美元升至39美元
07-30 11:45
今日重点评级关注:HC Wainwright & Co.:维持Q32 Bio"买入"评级,目标价从13美元升至36美元;Chardan Capital:维持ProMIS Neurosciences"买入"评级,目标价从20美元升至33美元
07-29 11:37
Piper Sandler analyst David Amsellem reiterates Alkermes (NASDAQ:ALKS) with a Overweight and raises the price target from $43 to $65.
07-28 23:59
华盛资讯7月28日讯,阿尔凯默斯公布2026财年Q2业绩,公司Q2营收4.96亿美元,同比增长26.9%,归母净利润0.01亿美元,同比下滑98.9%。
07-28 21:33
Alkermes shares are trading lower. The company reported Q2 financial results.
07-28 21:20
Alkermes (NASDAQ:ALKS) sees Q3 sales of $450.000 million-$470.000 million vs $472.751 million analyst estimate.
07-28 21:06
华盛资讯7月28日讯,阿尔凯默斯公布2026财年Q2业绩,公司Q2营收4.96亿美元,同比增长26.9%,归母净利润0.01亿美元,同比下滑98.9%。
07-28 19:46
Alkermes (NASDAQ:ALKS) affirms FY2026 sales outlook from $1.730 billion-$1.840 billion to $1.730 billion-$1.840 billion vs $1.812 billion estimate.
07-28 19:07
Alkermes (NASDAQ:ALKS) reported quarterly sales of $496.009 million which beat the analyst consensus estimate of $457.818 million by 8.34 percent. This is a 26.97 percent increase over sales of $390.657 million the same period last year.
07-28 19:02
今日重点评级关注:Needham:维持Immuneering"买入"评级,目标价从11美元升至18美元;富瑞:维持塞德斯医疗"买入"评级,目标价从90美元升至100美元
07-21 11:36